

## ChromaDex to Present at the 2015 Marcum MicroCap Conference on May 28, 2015

2015-05-18

IRVINE, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the **2015 Marcum MicroCap Conference**. The conference is being held on May 27 to 28, 2015 at The Grand Hyatt Hotel in New York City.

Mr. Jaksch is scheduled to present on Thursday, May 28 at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). ChromaDex management will also be attending one-on-one meetings with the investment community throughout the day.

The annual Marcum MicroCap Conference is a showcase for publicly traded companies under \$500 million in market capitalization. The conference attracts fund managers and high net worth investors focusing on small cap equities. Over 2,000 participants from all segments of the microcap market attend each year, including senior management, finance and legal executives, venture and lower middle-market private equity investors, institutional investors, directors, investment bankers, buy- and sell-side analysts, and service providers to the microcap marketplace.

For more information about the conference, visit: [www.marcumllp.com/microcap](http://www.marcumllp.com/microcap).

About ChromaDex:

ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned

synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure<sup>®</sup> pterostilbene; ProC3G<sup>®</sup>, a natural black rice containing cyanidin-3-glucoside; PUREENERGY<sup>®</sup>, a caffeine-pTeroPure<sup>®</sup> co-crystal; and NIAGEN<sup>®</sup>, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit [www.chromadex.com](http://www.chromadex.com).

#### Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

#### CONTACT: ChromaDex Company Contact:

Andrew Johnson  
Director of Investor Relations  
949-419-0288  
[andrewj@chromadex.com](mailto:andrewj@chromadex.com)

ChromaDex Investor Contact:  
The Del Mar Consulting Group, Inc.  
Robert B. Prag, President  
858-794-9500  
[bprag@delmarconsulting.com](mailto:bprag@delmarconsulting.com)

ChromaDex Corp